News
CTMX
--
0.00%
--
CytomX Therapeutics Stock Shows Every Sign Of Being Possible Value Trap
GuruFocus News · 1d ago
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics...
GlobeNewswire · 2d ago
JPMorgan: 2 Stocks for Stellar Long-Term Gains
According to JPMorgan CEO Jamie Dimon, the US is on the cusp of an economic boom which should fuel growth at least until 2023. Dimon attributes the prospect of strong growth to several reasons. “I have little doubt that with excess savings, new stimulus sa...
TipRanks · 2d ago
CytomX Therapeutics Shares Down 1.1% Ahead Of Virtual Investor Event Starting 1 p.m. EDT
CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its
Benzinga · 04/07 14:07
CytomX Therapeutics (CTMX) Receives a Buy from Mizuho Securities
SmarterAnalyst · 04/05 21:35
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 04/02 17:00
Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre
Zacks.com · 03/30 14:06
DJ CytomX Therapeutics Price Target Announced at $14.00/Share by JP Morgan
Dow Jones · 03/29 11:46
DJ CytomX Therapeutics Initiated at Overweight by JP Morgan
Dow Jones · 03/29 11:46
JP Morgan Initiates Coverage On CytomX Therapeutics with Overweight Rating, Announces Price Target of $14
JP Morgan analyst Anupam Rama initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Overweight rating and announces Price Target of $14.
Benzinga · 03/29 11:36
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics...
GlobeNewswire · 03/24 13:00
Thinking about buying stock in Ion Geophysical, OncoCyte, electroCore, CytomX Therapeutics, or Catalyst Biosciences?
NEW YORK, March 23, 2021 /PRNewswire via COMTEX/ -- NEW YORK, March 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, OCX,...
PR Newswire - PRF · 03/23 13:31
DJ CytomX Therapeutics Raised to Buy From Hold by Jefferies
Dow Jones · 03/23 11:40
Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA
Zacks.com · 03/22 12:21
BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up
Zacks.com · 03/10 15:12
Mizuho Securities Keeps a Buy Rating on CytomX Therapeutics (CTMX)
SmarterAnalyst · 03/09 14:35
8-K: CytomX Therapeutics, Inc.
(EDGAR Online via COMTEX) -- false 0001501989 0001501989 2021-02-26 2021-02-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/05 05:44
CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks.com · 03/02 22:46
Moving Average Crossover Alert: CytomX Therapeutics (CTMX)
Zacks.com · 03/02 16:46
Webull provides a variety of real-time CTMX stock news. You can receive the latest news about CytomX through multiple platforms. This information may help you make smarter investment decisions.
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.